Transepithelial transport of telmisartan in Caco-2 monolayers

被引:9
作者
Goto, Y
Itagaki, S
Umeda, S
Kobayashi, M
Hirano, T
Iseki, K
Tadano, K [1 ]
机构
[1] Sapporo City Gen Hosp, Dept Pharm, Sapporo, Hokkaido 0608604, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Clin & Pharmaceut & Therapeut, Sapporo, Hokkaido 0600812, Japan
关键词
telmisartan; monocarboxylate transporter; AT(1) receptor antagonist; Caco-2; cell; drug-drug interaction;
D O I
10.1248/bpb.28.2235
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Telmisartan is the most recently marketed angiotensin 11 type I receptor antagonist. Drug-drug interactions involving transporters can directly affect the therapeutic safety and efficacy of many important drugs. In clinical practice, telmisartan is coadministered with many kinds of drugs. However, little is known about the contribution of transporters to the intestinal transport of telmisartan. The aim of this study was to determine the transport mechanism of telmisartan across intestinal epithelial cells. In the presence of an inwardly directed proton gradient, the apical-to-basal transport of telmisartan was greater than basal-to-apical transport. Thus, we focused on the uptake mechanism of telmisartan across brush-border membranes. The uptake of telmisartan by Caco-2 cells was shown to be energy- and proton-dependent. Although some monocarboxylates inhibited the uptake of telmisartan, L-lactic acid, which is a typical substrate of the monocarboxylate transporter (MCT) 1-MCT4, did nor affect the uptake of telmisartan. Preloading of acetic acid enhanced the uptake of telmisartan, showing a trans-stimulation effect. These results suggest that the carrier-mediated transport system is involved in the uptake of telmisartan by Caco-2 cells and that the apical-localized transport system is similar to MCTs, but not MCT1-MCT4. It is possible that telmisartan reduce the absorption of coadministered drugs by sharing the MCTs. Since MCTs have an important role in the intestinal absorption of pharmacologically active compounds, it is important to be aware of the potential of telmisartan-drug interactions involving MCTs and to act in order to prevent undesirable and harmful consequences.
引用
收藏
页码:2235 / 2239
页数:5
相关论文
共 32 条
[11]  
Itagaki Shirou, 2003, Drug Metab Pharmacokinet, V18, P238, DOI 10.2133/dmpk.18.238
[12]   Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2 [J].
Itoh, T ;
Itagaki, S ;
Sumi, Y ;
Hirano, T ;
Takemoto, I ;
Iseki, K .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) :420-424
[13]  
Katsura Toshiya, 2003, Drug Metab Pharmacokinet, V18, P1, DOI 10.2133/dmpk.18.1
[14]  
Lacourciere, 1998, Blood Press Monit, V3, P295
[15]  
Lacourcière Y, 1999, INT J CLIN PRACT, V53, P99
[16]   pH and energy dependent transport of ketoprofen across rat jejunum in vitro [J].
Legen, I ;
Kristl, A .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 56 (01) :87-94
[17]  
Li YH, 1999, J PHARMACOL EXP THER, V290, P958
[18]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[19]   ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension [J].
Maillon, JM ;
Siche, JP ;
Lacourcière, Y .
JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (10) :657-664
[20]   Comparative safety and tolerability of angiotensin II receptor antagonists [J].
Mazzolai, L ;
Burnier, M .
DRUG SAFETY, 1999, 21 (01) :23-33